Nov 10 (Reuters) – Black Diamond Therapeutics Inc : * BLACK DIAMOND THERAPEUTICS – ANNOUNCES POSITIVE PHASE 2 SILEVERTINIB RESULTS AND FDA FEEDBACK FOR 1L EGFR-NCM NSCLC – SEC FILING * BLACK DIAMOND
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)